Neurogenic essential hypertension revisited: The case for increased clinical and research attention

American Journal of Hypertension

Volumn 16, Issue 10, 2003, Pages 881-888

  Mann, Samuel J ^a  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

Hypertension drug therapy; Sympathetic nervous system; blockers; blockers

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; CLONIDINE; DIHYDROPYRIDINE DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXAZOSIN; GUANADREL; GUANETHIDINE; LABETOLOL; METHYLDOPA; MOXONIDINE; RESERPINE; RILMENIDINE; TERAZOSIN; UNCLASSIFIED DRUG;

ADRENERGIC SYSTEM; ANTIHYPERTENSIVE ACTIVITY; BLOOD PRESSURE; CLINICAL FEATURE; COMORBIDITY; DISEASE MARKER; DRUG MECHANISM; ESSENTIAL HYPERTENSION; HUMAN; HYPERTENSION; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIDE EFFECT; SYMPATHETIC TONE;

EID: 0141674737     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0895-7061(03)00978-6     Document Type: Review

References (106)

1. Burt VL, Whelton P, Roccella EJ, Brown C, Cutler JA, Higgins M, Horan MJ, Labarthe D: Prevalence of hypertension in the U.S. adult population. Results from the third National Health and Nutrition Examination Survey. Hypertension 1995;25:305-313.
2. Materson BJ, Reda DJ, Cushman WC, Massie BM, Freis ED, Kochar MS, Hamburger RJ, Fye C, Lakshman R, Gottdiener J, Ramirez EA, Henderson WG: Single-drug therapy for hypertension in men. A comparison of 6 antihypertensive agents with placebo. N Engl J Med 1993;328:914-921.
3. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997;157:2413-2446.
4. Dahlof B, Hansson L, Acosta JH, Bolzano K, Fairhurst G, Ferreira C, Kaarsalo E, Silva MC, Simone A: Controlled trial of enalapril and hydrochlorothiazide in 200 hypertensive patients. Am J Hypertens 1988;1:38-41.
5. Mancia G, Grassi G, Giannattasio C, Seravalle G: Sympathetic activation in the pathogenesis of hypertension and progression of organ damage. Hypertension 1999;34:724-728.
6. Saxena PR: Interaction between the renin-angiotensin-aldosterone and sympathetic nervous systems. J Cardiovasc Pharmacol 1992;19(Suppl 6):S80-S88.
7. Mancia G, Saino A, Grassi G: Interactions between the sympathetic nervous system and renin angiotensin system, in Laragh JH, Brenner BM (eds); Hypertension: Pathophysiology, Diagnosis, and Management. New York, Raven Press, 1995, pp 399-407.
8. Ball SG: The sympathetic nervous system and converting enzyme inhibition. J Cardiovasc Pharmacol 1989;13(Suppl 3):S17-S21.
9. Giannattasio C, Cattaneo BM, Omboni S, Seravalle G, Bolla G, Turolo L, Morganti A, Grassi G, Zanchetti A, Mancia G: Sympathomoderating influence of henazepril in essential hypertension. J Hypertens 1992;10:373-376.
10. Grassi G, Turri C, Dell'Oro R, Stella ML, Bolla GB, Mancia G: Effect of chronic angiotensin-converting enzyme inhibition on sympathetic nerve traffic and baroreflex control of the circulation in essential hypertension. J Hypertens 1998;16:1789-1796.
11. Webb DJ, Seidelen PH, Benjain N, Collier JG, Struthers AD: Sympathetically mediated vasoconstriction is augmented by angiotensin II in man. J Hypertens 1988;6(Suppl 4):S542-S543.
12. Lee CC, Sidani MA, Hogikyan RV, Supiano MA: The effects of ramipril on sympathetic nervous system function in older patients with hypertension. Clin Pharm Ther 1999;65:420-427.
13. Ward R: Familial aggregation and genetic epidemiology of blood pressure, in Laragh JH, Brenner BM (eds): Hypertension, Pathophysiology, Diagnosis, and Management. New York, Raven Press, 1995, pp 67-88.
14. Luft FC: Molecular genetics of human hypertension. J Hypertens 1998;16:1871-1878.
15. Weinberger MH: Salt sensitivity of blood pressure in humans. Hypertension 1996;27:481-490.
16. He FJ, Markandu ND, Sagnella GA, MacGregor GA: Importance of the renin system in determining blood pressure fall with salt restriction in black and white hypertensives. Hypertension 1998;32:820-824.
17. Buhler FR: Calcium antagonists as first-choice therapy for low-renin essential hypertension. Kidney Int 1989;36:295-305.
18. Weinberger MH: Hypertension in African Americans: the role of sodium chloride and extracellular fluid volume. Sem Nephrol 1996;16:110-116.
19. Morgan RO, Anderson AIE, MacInnis RJ: ACE inhibitors, betablockers, calcium blockers, and diuretics for the control of systolic hypertension. Am J Hypertens 2001;14:241-247.
20. Freis ED: Age and antihypertensive drugs (hydrochlorothiazide, bendroflumethiazide, nadolol and capropril). Am J Cardiol 1988;61:117-121.
21. Mann SJ, Blumenfeld JD, Laragh JH: Issues, goals and guidelines for choosing first-time and combination antihypertensive drug therapy, in Laragh JH, Brenner BM (eds): Hypertension: Pathophysiology, Diagnosis, and Management. New York, Raven Press, New York 1995, pp 2531-2542.
22. Moser M, Lunn J: Responses to captopril and hydrochlorothiazide in black patients with hypertension. Clin Pharmacol Ther 1982;32:307-312.
23. Dickerson JEC, Hingorani AD, Ashby MJ, Palmer CR, Brown MJ: Optimisation of antihypertensive treatment by crossover rotation of four major classes. Lancet 1999;353:2008-2013.
24. Colombari E, Sato MA, Cravo SL, Bergamaschi CT, Campos RR Jr, Lopes OU: Role of the medulla oblongata in hypertension. Hypertension 2001;38:549-554.
25. Oparil S, Chen Y-F, Berecek KH, Calhoun DA, Wyss JM: The role of the central nervous system in hypertension, in Laragh JH, Brenner BM (eds): Hypertension: Pathophysiology, Diagnosis, and Management. New York, Raven Press, 1995, pp 713-740.
26. Chalmers J, Pilowsky P: Brainstem and bulbospinal neurotransmitter systems in the control of blood pressure. J Hypertens 1991;9:675-694.
27. Dimsdale JE, Moss J: Plasma catecholamines in stress and exercise. JAMA 1980;243:340-342.
28. Sullivan P, Schoentgen S, DeQuattro V, Procci W, Levine D, Van der Meulen J, Bornheimer J: Anxiety, anger and neurogenic tone at rest and in stress in patients with primary hypertension. Hypertension 1981;3(Suppl II):II119-II123.
29. Grassi G: Role of the sympathetic nervous system in human hypertension. J Hypertens 1998;16:1979-1987.
30. Anderson EA, Hoffman RB, Baron TW, Sinkey CA, Mark AL: Hyperinsulinemia produces both sympathetic neural activation and vasodilation in normal humans. J Clin Invest 1991;87:2246-2252.
31. Reaven GM, Lithell H, Landsberg L: Hypertension and associated metabolic abnormalities - the role of insulin resistance and the sympathoadrenal system. N Engl J Med 1996;334:374-381.
32. Jamerson KA, Julius S, Gudbrandsson T, Andersson O, Brant DO: Reflex sympathetic activation induces acute insulin resistance in the human forearm. Hypertension 1993;21:618-623.
33. Masuo K, Mikami H, Ogihara T, Tuck ML: Sympathetic nerve hyperactivity precedes hyperinsulinemia and blood pressure elevation in a young, non-obese Japanese population. Am J Hypertens 1997;10:77-83.
34. Strazzullo P, Barbato A, Vuotto P, Galletti F: Relationships between salt sensitivity of blood pressure and sympathetic nervous system activity: a short review of evidence. Clin Exper Hypertens 2001;23:25-33.
35. Jia H, Sharma P, Hopper R, Dickerson C, Lloyd DD, Brown MJ: Beta-2-adrenergic gene polymorphisms and blood pressure variations in East Anglian Caucasians. J Hypertens 2000;18:687-693.
36. Bray MS, Krushkal J, Li L, Ferrell R, Kardia S, Sing CF, Turner ST, Boerwinkle E: Positional genomic analysis identifies the beta2-adrenergic receptor gene as a susceptibility locus for human hypertension. Circulation 2000;101:2877-2882.
37. Timmermann B, Mo R, Luft FC, Gerdts E, Busjahn A, Omvik P, Li GH, Schuster H, Wienker TF, Hoehe MR, Lund-Johansen P: Beta2-adrenoreceptor genetic variation is associated with genetic predisposition to essential hypertension: the Bergen Blood Pressure Study. Kidney Intern 1998;52:1455-1460.
38. Hermann V, Buscher R, Go MM, Ring KM, Hofer JK, Kailasam MT, O'Connor DT, Parmer RJ, Insel PA: Beta2-adrenergic receptor polymorphisms at codon 16, cardiovascular phenotypes and essential hypertension in whites and African Americans. Am J Hypertens 2000;13:1021-1026.
39. Janetta PJ, Segal R, Wolfson SK, Dujovny M, Semba A, Cook EE: Neurogenic hypertension: etiology and surgical treatment. Ann Surg 1985;202:253-261.
40. Colon GP, Quint DJ, Dickinson LD, Brunberg JA, Jamerson KA, Hoff JT, Ross DA: Magnetic resonance evaluation of ventrolateral medullary compression in essential hypertension. J Neurosurg 1998;88:226-231.
41. Hohenbleicher H, Schmitz SA, Koennecke H-C, Offermann R, Offermann J, Zeytountchian H, Wolf K-J, Distler A, Sharma AM: Neurovascular contact of cranial nerve IX and X root-entry in hypertensive patients. Hypertension 2001;37:176-181.
42. Mann SJ: The mind-body link in hypertension: time for a new paradigm. Altern Ther Health Med 2000;6:39-45.
43. Jorgensen RS, Johnson BT, Kolodziej ME, Schreer GE: Elevated blood pressure and personality: a meta-analytic review. Psychol Bull 1996;120:293-320.
44. Suls J, Wan CK, Costa PT: Relationship of trait anger to blood pressure: a metaanalysis. Health Psychol 1995;14:444-456.
45. Mann AH: The psychological aspects of essential hypertension. J Psychosom Res 1986;30:527-541.
46. Hunyor SN, Henderson RJ: The role of stress management in blood pressure control: why the promissory note has failed to deliver. J Hypertens 1996;14:413-418.
47. Mancia G, Parati G: Reactivity to physical and behavioral stress and blood pressure variability in hypertension, in Julius S, Basset DR (eds): Handbook of Hypertension, Vol. 9: Behavioral Factors in Hypertension. Amsterdam, Netherlands, Elsevier Science, 1987, pp 104-122.
48. Parati G, Pomidossi G, Casadei R, Ravogli A, Groppelli A, Cesana B, Mancia G: Comparison of the cardiovascular effects of different laboratory stressors and their relationship with blood pressure variability. J Hypertens 1988;6:481-488.
49. Julius S, Amerena J, Smith S, Petrin J: Autonomic nervous and behavioral factors in hypertension, in Laragh JH, Brenner BM (eds): Hypertension, Pathophysiology, Diagnosis, and Management. New York, Raven Press, 1995, pp 2557-2569.
50. Weder AB, Julius S: Behavior, blood pressure variability and hypertension. Psychosom Med 1985;47:406-414.
51. Grassi G, Esler M: How to assess sympathetic activity in humans. J Hypertens 1997;17:719-734.
52. Eckberg DL: Spectral balance; a critical appraisal. Circulation 1997;96:3224-3232.
53. Wallace JD, Levy LL: Blood pressure after stroke. JAMA 1981;246:2177-2180.
54. Myers GM, Norris JW, Hachinski VC, Sole MJ: Plasma norepinephrine in stroke. Stroke 1981;12:200-204.
55. Roozekrans NTP, Porsius AJ, Van Zwieten PA: Comparison between the pressor response and the rise in plasma catecholamines induced by acutely elevated intracranial pressure. Arch Int Pharmacodyn 1979;240:143-157.
56. Silverberg DS, Oksenberg A, Iaina A: Sleep related breathing disorders are common contributing factors to the production of essential hypertension but are neglected, underdiagnosed, and undertreated. Am J Hypertens 1997;10:1319-1325.
57. Zwillich CW: Sleep apnea and autonomic function. Thorax 1998;53(Suppl 3):520-524.
58. Grote L, Hedner J, Peter JH: Sleep-related breathing disorder is an independent risk factor for uncontrolled hypertension. J Hypertens 2000;18:679-685.
59. Narkiewicz K, Somers VK: The sympathetic nervous system and obstructive sleep apnea: implications for hypertension. J Hypertens 1997;15:1613-1619.
60. Grassi G, Seravalle G, Cattaneo BM, Bolla GB, Lanfranchi A, Colombo M, Giannattasio C, Brunani A, Cavagnini F, Mancia G: Sympathetic activation in obese normotensive subjects. Hypertension 1995;25:560-563.
61. Owens PE, Lyons S, O'Brien E: Can heart rate predict blood pressure response to anti-hypertensive drug therapy? J Hum Hypertens 1998;12:229-233.
62. MacMahon S: Alcohol consumption and hypertension. Hypertension 1987;9:111-121.
63. Kawano Y, Abe H, Kojima S, Ashida T, Yoshida K, Imanishi M, Yoshimi H, Kimura G, Kuramochi M, Omae T: Acute depressor effect of alcohol in patients with essential hypertension. Hypertension 1992;20:219-226.
64. Mathias CJ: Management of hypertension by reduction in sympathetic activity. Hypertension 1991;17(Suppl 4):III69-III74.
65. Anderson GH Jr, Blakeman N, Streeten DH: The effect of age on prevalence of secondary forms of hypertension in 4429 consecutively referred patients. J Hypertens 1994;12:609-615.
66. Manger WM, Gifford RW Jr: Clinical and Experimental Pheochromocytoma. Cambridge, Blackwell Science, 1996.
67. Piccirillo G, Elvira S, Viola E, Bucca C, Durante M, Raganato P, Marigliano V: Autonomic modulation of heart rate and blood pressure in hypertensive subjects with symptoms of anxiety. Clin Sci 1998;95:43-52.
68. Julius S, Pascual AV, Sannerstedt R, Mitchell C: Relationship between cardiac output and peripheral resistance in borderline hypertension. Circulation 1971;43:382-390.
69. Julius S, Krause L, Schork NJ, Mejia AD, Jones KA, van de Ven C, Johnson EH, Sekkarie MA, Kjeldsen SE, Petrin J: Hyperkinetic borderline hypertension in Tecumsah, Michigan. J Hypertens 1991;9:77-84.
70. Markovitz JH, Matthews KA, Kannel WB, Cobb JL, D'Agostino RB: Psychological predictors of hypertension in the Framingham study: is there tension in hypertension? JAMA 1993;270:2439-2443.
71. Friedman R, Schwartz JE, Schnall PD, Landsbergis PA, Pieper C, Gerin W, Pickering TG: Psychological variables and hypertension: relationship to casual or ambulatory blood pressure in men. Psychosomatic Med 2001:63:19-31.
72. Mann SJ: Severe paroxysmal hypertension (pseudopheochromocytoma); understanding its cause and treatment. Arch Intern Med 1999;159:670-674.
73. Mann SJ: Severe hypertension paroxysmal. An autonomic syndrome and its relationship to repressed emotions. Psychosomatics 1996;37:444-450.
74. Isaksson H, Konarski K, Theorell T: The psychological and social condition of hypertensives resistant to pharmacologic treatment. Soc Sci Med 1992;35:869-875.
75. Mann SJ, Gerber LM: Psychological characteristics and responses to antihypertensive drug therapy. J Clin Hypertens 2002;4:25-34.
76. Pasik J, Shapiro D, Jamner LD, Hui KK: Hostility and the response to diuretic in mild-to-moderate hypertension. Am J Hypertens 1994;7:503-508.
77. Goldstein DS, Levinson PS, Zimlichman R, Pitterman A, Stull R, Keiser HR: Clonidine suppression testing in essential hypertension. Ann Intern Med 1985;102:42-48.
78. van Zwieten PA: The renaissance of centrally acting antihypertensive drugs. J Hypertens 1999;17(Suppl 3):S15-S21.
79. Hoffman BB: Catecholamines, sympathometic drugs, and adrenergic receptor antagonist, in Hardman JG, Limbird LE (eds): Goodman and Gilman's The Pharmacologic Basis of Therapeutics, Tenth Edition. New York, McGraw Hill, 2001, pp 220-226.
80. Andren L, Hansson L: Circulatory effects of stress in essential hypertension. Acta Med Scand Suppl 1981;646:69-76.
81. Lowenthal DT, Saris SD, Packer J, Haratz A, Conry K: Mechanisms of action and the clinical pharmacology of beta-adrenergic blocking drugs. Am J Med 1984;77:119-127.
82. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: Major cardiovascular events in hypertensive patients randomized to doxazosin vs. chlorothalidone. The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 2000;283:1967-1975.
83. Mills PJ, Dimsdale JE: Cardiovascular reactivity to psychosocial stressors. A review of the effects of beta-blockade. Psychosomatics 1991;32:209-220.
84. Ulrych M: Changes of general hemodynamics during stressful mental arithmetic and nonstressing quiet conversation and modification of the latter by beta-adrenergic blockade. Clin Sci 1969;36:453-461.
85. Lloyd-Mosten RH, Oram S: Modification by propranolol of cardiovascular effects of induced hypoglycemia. Lancet 1975;1:1213-1215.
86. Houben H, Thien T, van't Laar A: Effect of low-dose epinephrine infusion on hemodynamics after selective and nonselective beta-blockade in hypertension. Clin Pharmacol Ther 1982;31:685-690.
87. Andren L, Hansson L, Eggertsen R, Hedner T, Karlbert BE: Circulatory effects of noise. Acta Med Scand 1983;213:31-35.
88. Sinha R, Lovallo WR, Parsons OA: Cardiovascular differentiation of emotions. Psychosom Med 1992:54:422-435.
89. Julius S: The blood pressure seeking properties of the central nervous system. J Hypertens 1988;6:177-185.
90. Maconochie JG, Richards DA, Woodings EP: Modification of pressor responses induced by "cold." Br J Clin Pharmacol 1977;4:389P.
91. Pandhi PL, Sharma BK, Wahi PL: Comparative effect of propranolol and labetolol on isometric exercise and cold stress induced increase in areterial blood pressure. Int J Clin Pharmacol Ther Tox 1986;24:249-253.
92. Anand MP, Dattani KK, Datey KK: Effect of isometric exercise and mental stress on blood pressure - comparative effects of propanolol and labetolol. Indian Heart J 1984;36:4-7.
93. Dimsdale JE, Mills P, Ziegler M, Leitz K, Neleson R: Converting enzyme inhibition and blood pressure reactivity to psychological stressors. Hypertension 1992;20:210-213.
94. Shapiro AP: Pressor responses to noxious stimuli in hypertensive patients. Effects of reserpine and chlorothiazide. Circulation 1962;26:242-250.
95. Niarchos AP, Pickering TG, Morganti A, Laragh JH: Plasma catecholamines and cardiovascular responses during converting enzyme inhibition in normotensive and hypertensive man. Clin Exper Hypertens 1982;4:761-789.
96. Mann SJ, Pickering TG, Alderman MH, Laragh JH: Assessment of the effects of alpha and beta blockade in hypertensive smokers. Am J Med 1989;86:79-81.
97. Julius S, Jamerson K: Sympathetics, insulin resistance and coronary risk in hypertension: the chicken and egg question. J Hypertens 1994;12:495-502.
98. Prichard BNC, Richards DA: Comparison of labetolol with other anti-hypertensive drugs. Br J Clin Pharmacol 1982;13:41s-47s.
99. Mann SJ, Gerber LM: Low dose alpha/beta blockade in the treatment of essential hypertension. Am J Hypertens 2001;14:553-558.
100. Englert RG, Barlage U: The addition of doxazosin to the treatment regimen of patients with hypertension not adequately controlled by beta blockers. Am Heart J 1991;121:311-316.
101. Morgan T: Clinical pharmacokinetics and pharmacodynamics of carvedilol. Clin Pharmacokin 1994;26:335-346.
102. Searle M, Dathan R, Dean S, Christensen CC, Westheim A: Doxazosin in combination with atenolol in essential hypertension: a double-blind placebo-controlled multicentre trial. Eur J Clin Pharmac 1990;39:299-300.
103. Pool JL: Combination antihypertensive therapy with terazosin and other antihypertensive agents: results of clinical trials. Am Heart J 1991;122:926-931.
104. Holtzman JL, Kaihlanen PM, Rider A, Lewin AJ, Spindler JS, Oberlin JA: Concomitant administration of terazosin and atenolol for the treatment of essential hypertension. Arch Intern Med 1988;148:539-543.
105. Semplicini A, Pessina AC, Rossi GP, Hlede M, Morandin F: Alpha-adrenergic blockade by labetolol during long-term dosing. Clin Pharmac Ther 1983;33:278-282.
106. Richards DA, Prichard BNC: Clinical pharmacology of labetolol. Br J Clin Pharmac 1979;8:89S-93S.